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study was designed to determine QoL-based utilities 
speciﬁc to RGH. METHODS: Discrete choice conjoint
analysis (CA) and time trade off (TTO) exercises were
conducted using QoL states generated from six items
from the RGH Quality of Life Questionnaire (RGHQoL).
RGH patients completed tasks via interview. RESULTS:
One hundred ninety-two interviews were conducted (79
male, 113 female; age range 19–69 years, mean age 38.4).
For CA, all attributes were statistically signiﬁcantly inﬂu-
ential in determining preferences. The application of the
random effects probit model produced coefﬁcient values
that can be used as preference weights. For the TTO exer-
cise, coefﬁcient values (preference weights) were derived
by application of the random effects tobit regression
model. These coefﬁcient values can be used to derive rel-
ative and absolute utility values respectively. As the TTO
technique possesses cardinal properties, QALY scores 
can also be calculated. CONCLUSIONS: It is feasible to
generate both relative and absolute utility values from
responses to the RGHQoL questionnaire, allowing utility
to be based on true QoL. The ability to derive disease-
speciﬁc QoL-based utilities in this way means that the
same instrument can be used to generate both QoL and
utility data from the same clinical trial.
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OBJECTIVE: Patients with Alzheimer’s disease (AD)
have progressive cognitive, functional, and behavioral
decline, resulting in increased reliance on caregivers for
assistance with activities of daily living. Galantamine, a
novel treatment for AD with a dual mode of action
(acetylcholinesterase inhibition and allosteric nicotinic
receptor modulation), has demonstrated beneﬁts on cog-
nition, global function, activities of daily living, and
behavioral symptoms in patients with mild-to-moderate
AD. The objective of this study was to determine differ-
ences in caregiving time between caregivers of AD
patients receiving galantamine and those receiving no
treatment. METHODS: The analysis was based on data
from the AD Caregiver Project survey. Data were col-
lected using a self-administered questionnaire distributed
in December 2001 to a large national sample of unpaid
caregivers. Caregiver time was deﬁned as the number of
hours spent by the primary caregiver during a typical
week. Only patients living in the community were
included in the analysis. Using linear regression, caregiv-
ing times for galantamine-treated and untreated patients
were compared. Covariates included patient and care-
giver demographics, including employment status and
income level, and patient disease severity, functional
status, and living situation. RESULTS: Galantamine
patients (N = 97) differed from untreated patients (N =
803) with regard to gender (61% vs 35% males), age
(74.1 vs 79.6 years), and living situation (1% vs 6%
living alone). Caregivers of galantamine patients were
older (66.3 vs 59.2 years) and more likely to be a spouse
(77% vs 33%). After controlling for differences between
the groups, caregivers of galantamine patients provided
18 fewer hours of care per week than caregivers 
of untreated patients (95% CI: 3.3–32.5, p = 0.016).
CONCLUSION: Compared with untreated patients,
patients treated with galantamine appear to require sig-
niﬁcantly less caregiving time.
PNP2
IMPACT OF RIVASTIGMINE ON TIME TO FIRST
ANTIPSYCHOTIC DRUG USE IN PATIENTS
WITH ALZHEIMER’S DISEASE
Suh DC1,Arcona S2,Thomas S2, Chang S2, Powers C1
1Rutgers University, Piscataway, NJ, USA; 2Novartis
Pharmaceuticals Corporation, East Hanover, NJ, USA
OBJECTIVE: To investigate the effect of rivastigmine
treatment on the time to ﬁrst antipsychotic drug use
among patients with Alzheimer’s disease (AD), compared
to patients not treated with a cholinesterase inhibitor
(ChEI). METHODS: This study used MarketScan®
research databases from January 1, 1999 through Decem-
ber 31, 2001. Patient inclusion criteria included: (a) diag-
nosis of AD, (b) ≥65 years old at diagnosis, and (c)
continuous insurance coverage. Patients who previously
used any antipsychotics were excluded. Subjects were
classiﬁed into a ChEI group with the ﬁrst prescription
date as the index date or a non-ChEI group. Patients on
rivastigmine were further identiﬁed from the ChEI group.
Chi-square test, t-test, and log-rank test were used to test
differences in study variables between groups. Cox pro-
portional hazard models were used to estimate predicted
risk of the ﬁrst antipsychotic drug use. RESULTS: A total
of 2391 patients were included in the study (996 ChEI
and 1395 non-ChEI). ChEI users were younger compared
to non-ChEI users (79 vs. 81 years, P < 0.0001). However,
there were no signiﬁcant differences between antipsy-
chotic users and non-users, by age or gender. Over the
entire observation period, Kaplan-Meier analysis indi-
cated that users of ChEIs were 4% (relative risk (RR) =
0.96; 95% CI:0.77–1.18) less likely and patients taking
rivastigmine speciﬁcally (N = 214) were 19% (RR = 0.81;
95% CI:0.54–1.21) less likely to take antipsychotics as
compared to patients not taking ChEIs. After controlling
for demographic covariates, use of other psychotropics
and anticonvulsants, rivastigmine patients were 34% (RR
= 0.66; 95% CI:0.36–1.22) less likely to take antipsy-
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chotics. During the ﬁrst 150 days from the initiation 
of therapy, rivastigmine patients were 81% (RR = 0.19;
95% CI: 0.05–0.63) less likely to use antipsychotic drugs
compared to non-ChEI users. CONCLUSIONS: AD
patients who take rivastigmine are less likely to take
antipsychotics compared to those not taking ChEIs. These
ﬁndings imply that rivastigmine use may delay the 
progression of the development of behavioral symptoms
of AD.
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OBJECTIVES: This study explores the use of the WHO’s
ICIDH-2 in determining domains of mental functioning
impairment in migraineurs. METHODS: Seventy-one
migraine functioning questions were generated from
focus groups in the US and Germany and classiﬁed using
the ICIDH-2 system. A Phase I questionnaire imple-
mented in the US and Germany was used to identify items
of greatest relevance to migraineurs. Principal compo-
nents analysis (PCA) with Varimax rotation was used to
identify factors from relevant items in Phase I data. These
items were tested in a Phase II study in the US and
Germany and conﬁrmatory factor analysis (CFA) was
conducted to determine if the factor structure found in
Phase I remained intact. Statistics to assess ﬁt of the CFA
model included the chi-squared test which is insigniﬁcant
in good ﬁtting models, the RMSEA in which values less
than 0.05 indicate good ﬁt, and the NNFI which should
be at least 0.95 to indicate a strong model. RESULTS:
The Phase I PCA conducted in the US sample identi-
ﬁed four factors consistent with the ICIDH-2:
“Energy/Sleep”, “Perception”, “Attention/Thought”, and
“Emotion”. In Germany, the same factors were identiﬁed
with the exception of “Energy/Sleep”. Emotion items
were not included in Phase II in order to focus on func-
tioning alone. CFA of the Phase II data found that a
model including “Attention/Thought”, “Perception”, and
“Energy/Sleep” did not ﬁt well. After additional item
reduction, however, a model with “Perception” and
“Attention/Thought” showed excellent performance in
CFA with a chi-squared value of 33.04 (d.f. = 26, p =
0.16), RMSEA of 0.042 (90%CI 0.00–0.08) and NNFI
of 0.99. CONCLUSIONS: The ICIDH-2 mental func-
tioning dimensions with the greatest impact on
Migraineurs are Perception and Attention/Thought. Emo-
tional function was also an important factor. This
research supports the hypothesis that the ICIDH-2 can be
used in classifying areas of impairment for outcomes
assessment.
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OBJECTIVES: Attention deﬁcit hyperactivity disorder
(ADHD) is a prevalent mental health condition, occur-
ring in 3–5% of children. Although stimulant medications
are a recommended treatment for this disorder, physi-
cians’ views of these medications have not been system-
atically evaluated. This study examined physician
perceptions of using medications to treat ADHD symp-
toms in children and/or adolescents. METHODS: A
survey was developed with four physician experts in treat-
ing ADHD in children. The survey was pilot tested with
a sample of 10 practicing physicians. A sample of 1000
physicians, with a history of prescribing stimulant med-
ications to children and/or adolescents, was randomly
selected and mailed a 30-item survey. Items were rated on
a 7-point response scale (strongly agree, agree, slightly
agree, undecided, slightly disagree, disagree, strongly dis-
agree). RESULTS: A total of 365 physicians responded to
the survey, for a 36.5% response rate. Over 98% physi-
cians agreed that ADHD symptoms cause problems in
pediatric patients and that stimulants are effective in
treating ADHD. The stimulant side effects 
of decreased appetite/weight loss, sleep disruption, and
exacerbation of anxiety were a concern to 88%, 74%,
and 63% of physicians, respectively. Physicians reported
that controlled medications for children and/or adoles-
cents with ADHD are a burden for themselves (55%
agreed), for their staff (61% agreed), and for parents
(66% agreed). Diversion of ADHD medication was a
concern to 53% of respondents. Approximately 55% of
physicians responded that they would prefer prescribing
a non-stimulant medication with a FDA-indication for
treating children and/or adolescents instead of a stimu-
lant medication. CONCLUSIONS: Although physicians
overwhelmingly perceive stimulant medications as being
effective for treating ADHD symptoms in children and/or
adolescents, the majority would prefer a non-stimulant
medication. Their concerns related to side effects, diver-
sion, and burden of prescribing associated with stimu-
lants may be reasons for their preference.
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OBJECTIVES: Traditional database methodology suggest
patient selection be done through ICD codes when inter-
